上海君實生物醫藥科技股份有限公司
Shanghai Junshi Biosciences Co., Ltd.*
( 於中華人民共和國註冊成立的股份有限公司 )
股份代號 : 1877
2021
年度報告
* 僅供識別
2
4
14
16
57
69
86
142
169
173
175
177
179
182
280
2
2
1
3
2
1 3
4
Roy Steven Herbst
Roy Steven Herbst
2
3
9
10
7
8
8
9
8
10
5
6
3
910,756,700 219,295,700 H
36 58 2 10 1003 691,461,000 A
16 H
183 54 200 H
H
www.junshipharma.com
183 54
1
2021 11 2
2
2021 12 16
3
2021 8 30 2021 12 16
4
2021 6 29
5
2021 11 2
6
2021 11 2
7
2021 6 29
8
2021 6 29
H 01877 9
2021 4 29
A 688180
10
2021 4 29
4
2021 12 31 4,025 2020 152%
3,341 (i)
(JS016/LY-CoV016)
(ii) Coherus Coherus
2,069 2020 16%
(i) (ii)
(iii) 2020 A 2020 11
2,666 H 2021 6 23
2,105
895
120
719 2020 57%
5
(ADCs)
3
23 VV116
PARP III 25
2021 1
FDA (Fast Track
Designation)
IND FDA
III 2021 3 NMPA
2021 2 Coherus Coherus
Coherus
11.1
Coherus 1.5
2021 2
sNDA
NMPA 2021 11 NMPA
2021 2
sNDA NMPA
2021 1 2 TAB006/JS006 TIGIT NMPA FDA IND
6
2021 2 JS110 XPO1 JS111 EGFR exon20
IND NMPA 2021 4 IND
2021 2 JS201 PD-1/TGF-β IND NMPA
2021 5 IND
2021 3 FDA
BLA (Rolling review) FDA BLA PD-1
2021 8
FDA 2021 9 BLA 2021 10
BLA FDA FDA BLA
BLA (PDUFA)
2022 4
2021 3 JS103 IND NMPA 2021 5
IND
2021 3 JS007 CTLA-4 IND NMPA 2021 6
IND
2021 4
12
sNDA NMPA
2021 4
III JUPITER-06 NCT03829969 IDMC
PFS OS
2021 6 JS014 21 (HSA) IND
NMPA 2021 8 IND
2021 7
sNDA NMPA
7
2021 8 UBP1213sc B (BLyS) IND
NMPA 2021 11 IND
2021 9 JS012 Claudin18.2 IND NMPA 2021
11 IND
2021 10 JS019 CD39 IND
NMPA 2021 12 IND
2021 10 JS026 COVID-19 IND NMPA
2021 11 IND
2021 11 JS112 Aurora A IND NMPA 2022 2 IND
2021 12 JS107 Claudin18.2 MMAE IND NMPA
2022 3 IND
2021 12 JS001sc
IND NMPA 2022
3 IND
2021 12
sNDA
NMPA
8
COVID-19
(JS016/LY-CoV016) 2020
2021 2 FDA
EUA COVID-19 12 COVID-19
2021 9 FDA EUA 12
COVID-19
2021
12 FDA EUA 12
COVID-19 15
70
3.5 1.4
VV116 JT001 2021 9
SARS-CoV-2 VV116
VV116
COVID-19 COVID-19 VV116
III
COVID-19 II/
III (NCT05242042) VV116 COVID-19
VV993 JT003 3CL SARS-CoV-2
VV993
9
2021 7 mRNA
50% 50%
mRNA
2021
12
PD-1
412 2020 2021 3
2020 60%
2021
2021
PD-1
2021
10
2021 11
2021 12
102
2021 11 11 51
50%
III
2021 6 H 70.18 36,549,200
H 2,105
2021 12 A 14 A 12.75
11
2022 2
III
JUPITER-15 NCT05180734
2022 3
NMPA
2022 3 JS105 PI3K-α IND NMPA
2022 3 JS116 KRASG12C IND NMPA
2022 1 Coherus 2021 2 Coherus
TAB006/JS006 Coherus TAB006/JS006
TAB006/JS006 Coherus 3,500
Coherus 2.55
TAB006/JS006 Coherus 18%
2022 3
JS120 IDH1 JS121 SHP2 JS122 FGFR2
JS123 ATR
2022 3 GMP
CGMP
30,000
2022 3 7,000 A
39.8
12
12 31
2017 2018 2019 2020 2021
1,148 934 775,089 1,594,897 4,024,841
702 667 684,405 1,222,366 2,766,654
(320,802) (716,500) (744,233) (1,665,639) (728,181)
(326,915) (714,593) (741,055) (1,687,567) (718,579)
(326,688) (714,654) (740,744) (1,687,567) (718,557)
(227) 61 (311) – (9,624)
(0.55) (1.19) (0.95) (2.02) (0.80)
(1.19) (0.95) (2.02) (0.80)
12 31
2017 2018 2019 2020 2021
708,703 1,347,126 2,511,324 3,312,147 5,218,981
511,006 2,910,184 1,911,116 4,698,717 5,831,739
1,219,709 4,257,310 4,422,440 8,010,864 11,050,720
41,815 465,112 828,548 677,022 701,903
58,560 471,065 605,376 1,492,582 2,016,635
100,375 936,177 1,433,924 2,169,604 2,718,538
1,119,334 3,321,133 2,988,516 5,841,260 8,332,182
2017
13
12 31
2017 2018 2019 2020 2021
*
54,500 2,928 775,089 1,594,897 4,024,841
48,373 (1,269) 677,105 1,214,645 2,773,235
(317,571) (722,854) (747,729) (1,668,607) (730,534)
(326,915) (721,582) (744,550) (1,690,536) (720,932)
(0.55) (1.21) (0.96) (2.03) (0.81)
(2.03) (0.81)
12 31
2017 2018 2019 2020 2021
704,380 1,340,137 2,500,838 3,298,693 5,190,020
515,328 2,910,184 1,911,116 4,698,717 5,844,891
1,219,708 4,250,321 4,411,954 7,997,410 11,034,911
41,815 465,111 855,700 697,140 717,084
58,560 471,067 578,225 1,472,464 2,001,453
100,375 936,178 1,433,925 2,169,604 2,718,537
1,119,333 3,314,143 2,978,029 5,827,806 8,316,374
*
14
2021
15 EUA
70 3.5 1.4
VV116
3CL VV993 VV116
VV993
2021 Coherus
FDA BLA
2021
15 30 2022
III
15
2021
IL-21 CD112R(PVRIG)
TAB004/JS004 BTLA
2022
2021
H
51 (ADCs)
2022 3 31
16
first-in-class
best-in-class
JS001
NMPA PD-1
12
UBP1213
NMPA IND PCSK9 BLyS TAB004/JS004
(first-in-human) BTLA FDA NMPA
Ib/II SARS-CoV-2
15
SARS-CoV-2 VV116 III
(ADCs)
COVID-19
17
102 2021 11
11 51
2021 2
NMPA
2021 4
12
NMPA 2021 7
sNDA NMPA 2021 11
sNDA NMPA 2021 12
sNDA NMPA sNDA PD-1
2021
2021
12
PD-1
2021 2
2021 12 31
18
15 30
FDA 2 1 1
4
2021 3 FDA
BLA FDA (Rolling Review)
FDA
BLA PD-1 2021 8
FDA FDA
FDA 2021 9
BLA 2021 10 BLA
FDA FDA BLA
BLA (PDUFA) 2022 4
2021 6 ASCO (ASCO 2021)
39 1
1 15
10 ASCO 2021 LBA Late-
breaking Abstract
JUPITER-02
#LBA2
BTLA (TAB004/JS004)
19
COVID-19
2020
2021 2 FDA EUA COVID-19
12 COVID-19 2021 9 FDA EUA 12
COVID-19
2021
12 FDA EUA 12
COVID-19 15
70 3.5
1.4
VV116(JT001) 2021 9 SARS-CoV-2 VV116
VV116 COVID-19
3 I Acta Pharmacologica Sinica
VV116
200 600 COVID-19
VV116 III
COVID-19 II/III
(NCT05242042) VV116 COVID-19
20
VV993(JT003) 3CL SARS-CoV-2 VV993
VV116 VV993
VV993
mRNA
2021 2 Coherus
Coherus Coherus
Coherus 11.1 Coherus
20%
Coherus 1.5 2022 1 Coherus
Coherus TIGIT
TAB006/JS006 Coherus TAB006/JS006 TAB006/JS006
Coherus 3,500
Coherus 2.55 TAB006/JS006 Coherus
18% Coherus
Coherus
Coherus TAB006/JS006
50% mRNA 50%
mRNA
mRNA
mRNA
21
(ADCs)
3
23 VV116 PARP
III 25 TAB006/
JS006 TIGIT JS110 XPO1 JS111 EGFR exon20
JS201 PD-1/TGF-β JS103 JS007 CTLA-4
JS014 21 (HSA) UBP1213sc B
(BLyS) JS026 COVID-19 JS012
Claudin18.2 JS019 CD39 JS107 Claudin18.2
MMAE JS001sc
JS112 Aurora A NMPA FDA
IND 2022
IND
2,805 896 846 742
IT
22
ESG
H 70.18 36,549,200 H
2,105
2021 12 A 14 A 12.75
3,505 2022 3
A 7,000 A 39.8
2021 2 A H 2021 3 A 50
H
2021 9 A MSCI A
ESG Wind ESG A AA
(license-in)
(ADCs)
3 23
PARP VV116 III 25
23
NCT03013101 2018 12 17 NMPA
2021 2 NMPA FDA BLA FDA
NCT02915432
2021 4 NMPA
NCT03113266
2021 11 NMPA FDA BLA
NCT03581786 FDA
NDA
NCT03829969 FDA
NDA
NCT03856411 EGFR
NCT03924050 EGFR TKI
NCT04772287
NCT04012606
NCT04848753
JS001 NCT03430297
NCT04085276
NCT04523493
NCT04723004
NCT03859128
NCT02915432
NCT04394975
NCT04568304 PD-L1+
NCT05180734
FDA
/
NMPA
NCT03474640 FDA
JS011 JS113 JS207 JS001sc JS019 JS112 JS004(TAB004) JS109
EGFR 4th Gen PD-1+ PD-1 CD39 Aurora A BTLA PARP PD-1
JS013 JS114 JS209 JS003 JS101 JS201 JS005
CD93 Nectin4 ADC CD112R+TIGIT PD-L1 Pan-CDK PD-1/TGF- IL-17A VEGF TNF-
JS015 JS115 JS211 JS006(TAB006) JS107 JS103 *
DKK1 BCMA ADC PD-L1+ TIGIT Claudin18.2 ADC Uricase PCSK9 S
JS018 JS116 JS007 JS108 UBP1213sc JT001(VV116)
JS008
IL-2 KRAS CTLA-4 Trop2 ADC BLyS RdRp
JS104 JS203 JS401 JS012 JS110 JS026
Pan-CDK CD3+CD20 (RNAi) Claudin 18.2 XPO1 S
JS105 JS206 JS010 JS014 JS111
PI3K- IL-2+PD-1 CGRP IL-21 EGFR exon 20
JS120 JS121 JT003(VV993)
IDH1 SHP2 3CL
JS122 JS123 JT109
FGFR2 ATR
* FDA
JS009(TAB009)
CD112R/PVRIG
24
25
PD-1
2
2018 12 17
NMPA
2021 2
NMPA 2021 4
12
NMPA 2021 7
sNDA NMPA 2021 11
NMPA 2021 12
sNDA NMPA
CSCO CSCO CSCO CSCO
CSCO
2021
12
PD-1
26
412 2020 2021 3
2020 60%
2021
2021
PD-1
2021
27
2021 11
2021 12
102
2021 11 11 51
50%
III
15 30
28
2021 2
sNDA
NMPA 2021 11 NMPA sNDA JUPITER-02
(NCT03581786) III
III
JUPITER-02 IDMC
PFS ORR DoR
PFS 11.7 8.0 1 PFS 49.4% 27.9% PD-L1
PFS
ORR
77.4% 66.4% DoR 10.0 5.7 2021 6 ASCO
LBA Latebreaking Abstract
2021 3
NMPA
2021 4
III JUPITER-06 NCT03829969 IDMC
PFS OS 2021 7
sNDA NMPA 2021 9 2021
(ESMO) 2021 3 22
PFS 42%
OS OS 17.0 11.0 6
29
2021 12
sNDA
NMPA sNDA III CHOICE-01
NCT03856411 CHOICE-01 2021 9 2021 (WCLC)
2022 3 2022 ASCO (ASCO Plenary Series)
EGFR/ALK
PFS 51% OS vs17.1
31%
III (NCT04012606)
III (NCT03859128)
III (NCT04723004)
III (NCT05180734)
FDA 2
1 1 4
– 2021 1
IND FDA
III
2021 2 Coherus Coherus
Coherus
1.5
3.8
Coherus
20%
30
2021 3 FDA
BLA FDA
FDA BLA PD-1 2021 8
FDA
FDA
FDA 2021 9
BLA 2021 10 BLA
FDA FDA BLA
BLA (PDUFA) 2022 4
2021 1 21 (WCLC 2020)
CIK
2021 1 (Journal of Clinical Oncology,IF: 44.544)
(POLARIS-02)
2021 1 Therapeutic Advances in Medical Oncology, IF: 8.168
2021 4 AACR (AACR 2021)
3
2021 6 (ASCO 2021)
39 1
1 15
10
ASCO 2021 LBA
JUPITER-02 #LBA2
31
2021 6 29 (ESTS 2021)
2021 9 (WCLC 2021)
(NSCLC) III CHOICE-01
IIIA-IIIB NSCLC
(PSC)
2021 9 (ESMO 2021)
11
III JUPITER-06
2021 9
III JUPITER-02
Nature Medicine IF: 53.440
26
2022 2
(NCT03086174) 3
Journal for ImmunoTherapy of Cancer IF
13.751
2022 3 JUPITER-06 Cell Press Cancer Cell IF:31.734
TP +
PFS OS
32
JS016/LY-CoV016
SARS-CoV-2
C O V I D -19 2021 2 FDA EUA
COVID-19 12 COVID-19 2021 9 EUA
2021 12 EUA 12
COVID-19
15
I (NCT04441918) COVID-19 Ib/II
(NCT04780321)
33
I
(NCT04441931) COVID-19 II/III (BLAZE-1, NCT04427501)
BLAZE-1 III 1,400
700 COVID-19 COVID-19
769 0.78% 4 5.81% 15
87%(p<0.0001) 4
BLAZE-4 (NCT04634409)
1,400 700
2,800 2,800
2021 1 The Journal of the American Medical Association,
JAMA, IF: 56.272 COVID-19
BLAZE-1
2021 5 Antimicrobial Agents and Chemotherapy AAC, IF:
4.904 I
I
2021 7 The New England Journal of Medicine,
NEJM, IF: 91.245 COVID-19 III
(BLAZE-1)
UBP1211
2022 3
NMPA
50:50
34
JS002
PCSK9
I II
(LDL-C) 55-70%
III
2021 III
II 2021
PCSK9
BTLA TAB004/JS004
TAB004/JS004 (first-in-human) B T
(BTLA) BTLA TAB004/JS004 Ib/II
TAB004/JS004
TIGIT TAB006/JS006
TAB006/JS006 TIGIT TAB006/JS006
TIGIT-PVR TIGIT T cell immunoglobulin and
ITIM domain, T ITIM NK T
PVR NK T
PD-1 T TIGIT PD-1/PD-L1
2021 1 TAB006/JS006 NMPA IND
2021 2 TAB006/JS006 FDA IND TAB006/
JS006
2022 1 Coherus 2021 2 Coherus
TAB006/JS006 Coherus TAB006/JS006 TAB006/JS006
Coherus 3,500
Coherus 2.55 TAB006/JS006 Coherus
18%
35
CTLA-4 JS007
JS007 CTLA-4 T
4 Cytotoxic T lymphocyte-associated antigen-4 CTLA-4 T
JS007 CTLA-4 CTLA-4 B7 CD80 CD86 T
ipilimumab
JS007 ipilimumab
2021 4 JS007 IND NMPA 2021 6 IND
Trop2 Tub196 JS108
JS108 Trop2 Tub196 Trop2
Trop2
JS108 I (NCT04601285) I JS108
3 3
16-36 12-27 60-90
PARP senaparib JS109
Senaparib ADP (PARP)
2020 8 senaparib
PARP senaparib
50% 2020 8 20 2020 8
26 senaparib III
36
PD-1/TGF-β JS201
JS201 PD-1 TGF-β β PD-1
TGF-β TGF-β PD-1
PD-1 TGF-β JS201 PD-1/PD-L1 TGF-β
2021 2 JS201 IND NMPA 2021 5 IND 2021 7
JS201 I (NCT04956926) JS201
XPO1 JS110
JS110 XPO1 JS110
XPO1 p53 JS110
JS110
JS110 2021 2 JS110 IND
NMPA 2021 4 IND JS110 I (NCT04991129)
EGFR exon20 JS111
JS111 EGFR EGFR EGFR
10% EGFR exon20 T790M G719X
18-21 EGFR-TKI EGFR exon20 EGFR
JS111
T790M EGFR EGFR EGFR exon20
EGFR JS111 EGFR exon20 EGFR
2021 2 JS111 IND NMPA 2021 4 IND
JS111 I/II (NCT04993391) JS111
37
JS103
JS103
(2019)
13.3% 1.1% JS103
2021 3 JS103 IND NMPA 2021 5
IND I
IL-17A JS005
JS005 IL-17A JS005 IL-17
JS005
JS005 I
II
21 (HSA) JS014
JS014 21 (HSA) HSA
IL-21 IL-21R
JS014 2019 6 Anwita Biosciences,
Inc. Anwita
JS014 2021 6 JS014 IND NMPA 2021 8 IND I
Claudin18.2 JS012
JS012 Claudin18.2 Claudin18.2
(ADCC) (CDC)
2021 9 JS012 IND NMPA 2021 11 IND
38
Claudin18.2 MMAE JS107
JS107 Claudin18.2 MMAE(Monomethyl auristatin E)
Claudin18.2 (ADCs) JS107
Claudin18.2 MMAE
JS107 (ADCC) (CDC)
MMAE JS107
JS107 2021 12 JS107 IND
NMPA 2022 3 IND
CD39 JS019
JS019 CD39 CD39
(ATP) (ADO)
CD39
2020 9 CD39
2021 10 JS019 IND NMPA 2021 12 IND
VV116 JT001
VV116 SARS-CoV-2 SARS-CoV-2 VV116
SARS-CoV-2 SARSCoV-2 Alpha Beta Delta Omicron
2021 9
VV116
3 I NCT05227768 NCT05201690 NCT05221138 Acta
Pharmacologica Sinica VV116
200 600
I COVID-19
II/III (NCT05242042) VV116 COVID-19
COVID-19 VV116
III
39
2021 7 50%
2021 7 19 2021 7 23 mRNA
mRNA
2 GMP 4,500L (9*500L) 3,000L
1,500L
CGMP 30,000L
15*2,000L 2019 JS016
2022 3 GMP
40
2,069
16% 108 84
24
2021 6
H 70.18 36,549,200 H
2,105
2021 12 A 14 A 12.75
2021 2 A H 2021 3 A
50 H
2021 9 A MSCI A
ESG Wind ESG A AA
41
1.
2021 12 31 4,025 152% (i)
427 61%
412 2020 2021
3
2020 60%
2021
(ii) 3,341
a 2020 5
b Coherus 2021 2
Coherus Coherus
2.
2021 12 31 2,069 2020 291
16% 1,467 408
80 54 60
2020 2% 68% 82% 391% 54% (i)
(ii) (iii)
2020 A
3.
2021 12 31 735 2020 47
7% 2021
42
4.
2021 12 31 648 2020 205
46% 251 118
108 101 70
2020 2% 26% 66% 742% 169% 2021 (i)
(ii)2020 11 A
5.
2021 12 31 2020 12 31 3,385 3,505
(i) H (ii)
2021 12 31 114 654
2021 6
6.
43
12 31
2021 2020
(718,579) (1,687,567)
– 1,102
192,754 30,728
39,937 11,672
(485,888) (1,644,065)
7.
H H H
3,003 2021 12 31 12
H
2018 12 11 2019 8 29 2019 2020 8
28 H
44
2019 2020
2021 2021
12 31 12 31
2019 12 31 2020 6 30
3
1,952,203 65% 2,162,440 72% 2,372,677 79% 2,361,794 10,883 2022
12 31
JS001 1,201,356 40% 1,201,356 40% 1,291,457 43% 1,287,010 4,447 2022
12 31
480,542 16% 480,542 16% 600,678 20% 594,242 6,436 2022
JS004 1a
12 31
270,305 9% 480,542 16% 480,542 16% 480,542 – 2021
1b
12 31
750,847 25% 540,610 18% 330,373 11% 329,802 571 2022
1c
12 31
300,339 10% 300,339 10% 300,339 10% 334,570 2
301 2
2022
12 31
3,003,389 100% 3,003,389 100% 3,003,389 100% 3,026,166 11,755
1. 2019 2019 8
a.
b.
c.
2. 35
3.
4.
45
[2020]940 2020 7
A 8,713 55.50 4,836
339 4,497 A
2020 6 22 A
2021 2021
12 31 12 31
1,200,000 1,089,818 110,182 2023 12 31
700,000 700,000 – 2020 12 31
800,000 784,030 15,970 2023 12 31
1,796,978 552,686 1,244,292 2023 12 31
4,496,978 3,126,534 1,370,444
46
2021 2020 12 31
(a)
12 31
2021 2020
(718,557) (1,665,639)
12 31
2021 2020
892,659,689 824,816,637
(b)
2018 5 14 2020 11 16 2021 11 15
2021 12 31 2020
12 31 2021
2020 12 31
2021 4 30 20,000,000 50%
2021 7 19 50,000,000 50%
Anwita
355,084,000
47
12 31
2021 2020
– 17
a 155,218 77,030
b 46,664 133,007
c 551,651 146,688
d 20,000 –
773,533 356,725
e 253,575 –
1,027,108 356,725
(a)
(b)
(c)
78,569,000 2020 68,199,000
(d) 20,000,000 4,687,301
3
(e) Coherus
48
2020 12 31 343 2021 12 31 485
12 31
2021 2020
353,059 277,288
102,665 31,887
28,877 34,250
484,601 343,425
2020 12 31 663 2021 12 31 1,293
12 31
2021 2020
1,285,243 589,207
7,690 74,116
1,292,933 663,323
– –
1,292,933 663,323
2020 1 1 157,416,000
49
12 31
2021 2020
0 30 1,285,217 573,437
31 90 26 27,876
91 180 – 61,103
180 7,690 907
1,292,933 663,323
2021 12 31 2020 12 31
61,583,000 90
2021 12 31 7,690,000 2020
74,116,000
50
12 31
2021 2020
196,205 90,706
89,874 106,018
a 227,709 215,933
64,569 31,656
54,149 48,330
b 932,509 210,552
c 15,742 30,149
– 64,354
213,777 205,026
20,579 19,620
d – 68,199
– 32,625
H 757 –
91,653 91,848
1,907,523 1,215,016
51
8,400,000 1,224,000
2020 Anwita
15 60 2020 15 60
12 31
2021 2020
0 30 143,117 74,433
31 60 32,625 4,316
61 180 13,473 2,009
180 6,990 9,948
196,205 90,706
(a)
(b) 5
30
(c)
(d)
52
2021 12 31
500 2021 7 30 2028 7 28
3.90%
i) ii)
2021 12 31
12 31
2021 2020
664,538 1,716,673
55,611 58,862
720,149 1,775,535
10,596 252,346
30,000 542,222
220,000 –
240,000 –
500,596 794,568
2021 2020 12 31
53
2021 12 31
664 2020 12 31 528 26%
7,000 A 39.8
5,700
100% 2021 12 31
54
2021 12 31 2,805
2020 A
7,129,000 2020 A
1.
2019
2.
55
3.
PD-1 PD-1
4.
2021
2021
PD-1
56
5.
4+7
UBP1211 JS501
6.
7.
57
48
2015 3
2013 4
2013 1 2013 3 2015 11
430598.NEEQ 2016 6
2013 9 2015 11 2007 2
1996 7 2007 12
2017 2021 12 31
218,552,586 A 2,600 H
58
60
2018 6
2018 1
1994 5 1997 1 (NIH) AIDS
WESTAT 1997 2 2009 12 FDA
2009 9 2018 1
2007 1 2010 12 (Johns Hopkins)
2010 11 2012 11 2012 1 2014 12
1984 7 1987 10
1994 8
2021 12 31 1,560,000 A
57
2016 12
2016 12
18 1986 7 1997 12
1997 12 2004 1
2004 1 2019 3
600867.SH 2019
6
1986 7
2021 12 31 3,657,600 A
59
45
2015 3
2014 1
10
2003 2007 2007 2010 HumanZyme
Inc. 2010 10 2013 11 MedImmune Inc.
TopAlliance
JS001 JS002 JS003
1997 7 2003 9
2021 12 31 13,960,000 A
54
2016 12
2012 12
20 2011 11 2015 11
2008 7 2015 11 2013 10
2016 5 2018 6 2016 4
2021 9
2012 12 2012 12 2013 3
2013 10
60
1997 1 2004 5
2005 5 2008 10 Viron Therapeutics Inc. 2008 11 2011 9
2011 2
1988 7 1995 7
2005
2021 12 31 9,428,000 A
46
2016 12
2014 6
2004 5 2010 12
2011 1 2011 10 2011 10 2014
6 Amplimmune Inc.
TopAlliance JS002 JS003
1998 6 2003 1
(Nature Communications)
(Science Advances) (Immunity) Jem Blood JI
2021 12 31 2,000,000 A
61
48
2016 12
2013 6
20 2003 3 2007 9
2007 8 2009 2 Trellis Biosciences 2009 2 2013 5 Amgen
2015 3 2020 10 2016 12
2020 10 14 JS002 JS003
1994 7 2002 5
(Nature) (Science) (EMBO)
20
53
2015 5
2015 5
20 1991 1993
1993 1996 1996 6
2010 12
2010 10 2013 10
002650.SZ 2011 6 2018 11
832549.NEEQ 2017 8 2013 4
2013 7
2017 7
1989 7 1990 1
2021 12 31 204,646,286 A 2,600 H
62
48
2018 6
2018 6
2015 9 2015 6
1997 7 2001 7
2004 5 2015 4 2015 7 2021
2
836484.NEEQ 2017 6 2021 4
2120.HK 2018 11 2021 3
9969.HK 2019 11 2020 8
9926.HK
2014 6 2017 3
600649.SH 2017 9 2020 10
600825.SH 2016 4 2020 9
YIN.US 2016 3 2019 6
3666.HK 2015 11 2019 3
0376.HK 2020 4 2021 5
002793.SZ
1994 6 1997 6
2003 6
2021 12 31 78,852,000 A 37,189,000 H
63
64
2018 6
2018 6
35 1999 B7-H1 PD-L1
PD-L1 1999 2002 PD-1/PD-L1
2006 PD-1 PD-L1
1990 1997 (Bristol-Myers Squibb
Company) 1997 1999 2004 2011
2011
2017 4 17
138.25
14.63%
2016 9 27 307.5
1982 1986 1989
William B. Coley 2014 AAI-Steinman 2016 Warren Alpert 2017
2018
64
Roy Steven Herbst 59
2018 6
2018 6
Herbst 1991 1997 1998 2011
(UTMDACC) Barnhart
2011 3
Smilow Cancer Hospital I
Herbst 1984 6 1990 6
1991 5 Cornell University Medical College
1997 11 2012 12
53
2018 6
2018 6
1989 8 1995 3 1995 3 1999 7
1999 7 1999 12 2000 1 2006 3
2006 3
1989 7 2004 12 2015
11 2017 9
2017 12
65
64
2020 6
2020 6
1978 8 1992 7
1992 8 1993 12 1993 12 1995 12
1995 12 1999 12
1999 12 2010 9 2010 9 2017 8
2017 8
1985 7 2001 12 1994
1997 12
65
2021 12
2021 12
1975 12 1978 2 1982 12 2016 11
2000 4 2008 5 2007
5 2011 6 2011 5 2015 7
2016 8 2016 11
2018 1 2018 10
1982 12 1988 12
66
36
2018 6
2018 6
2011 3 2014 3 2016
1 2017 4 華泰證券股份有限 2017 10
2008 7 2011 1
40
2018 6
2018 6
2006 3 2003 6
2006 1 2006 9
31
2021 6
2021 4
2021 4 2021 9
2016 11 2017 5 NBC
2018 4 2018 6 2018 7 2021 3
ABB
2014 2016
67
64
2019 8 1995 10
1998 6 1998 6 1999 7 Osiris
Therapeutics 1999 8 2003 8 2003 8 2005
6 2005 6 2017 4 FDA
2017 4 2018 4 NMPA
2018 5 2019 8 2021 1
688238.
SH 2021 6 1995
43
2020 11 2004 6 2011 5
2011 5 2013 4
2013 4 2020 2 2020 2 2020 11
2004
30
2018 1 2017 4 2017 4 2018 1
2014 7 2015 11
2017 11
2019 10
68
20
69
70
14 6 3 5
2021 11 2
2021 6 29
Roy Steven Herbst
2021 12 16
2021 8 30 2021 12 16
57 68
71
3.13
B.2.2
72
73
2021 12 31
A/B
A/B
2021 11 2 A/B
A/B
A/B
A/B
A/B
A/B
A/B
2021 6 29 A/B
A/B
Roy Steven Herbst A/B
A/B
A/B
2021 12 16 B
2021 8 30 2021 12 16 A/B
A
B
74
3.10(2)
(i)
(ii) (iii)
2020 A
12
75
2022
12 31
76
48 7 2015 3 27
60 3 2018 6 24
2021 11 2 57 5 2016 12 22
45 7 2015 3 27
54 5 2016 12 22
46 5 2016 12 22
48 5 2016 12 22
53 6 2015 5 30
48 3 2018 6 24
2021 6 29 50 5 2016 12 22
64 3 2018 6 24
Roy Steven Herbst 59 3 2018 6 24
53 3 2018 6 24
64 2 2020 6 19
2021 12 16 65 1 2021 12 16
2021 8 30 57 2 2020 11 16
2021 12 16
2021 12 31 1,343 (47.88%) 1,462 (52.12%)
77
1.
2.
a)
b)
c)
d)
e)
f)
g)
h)
78
Roy Steven Herbst
A.2
79
(1)
10/10 – 2/2 3/3 1/1 4/4
10/10 – 2/2 – 1/1 4/4
2021 11 2 10/10 5/5 – – – 4/4
10/10 – – – – 4/4
10/10 – – – – 4/4
10/10 – – – – 4/4
10/10 – – – – 4/4
10/10 0/5 – – – 4/4
10/10 – – – – 4/4
2021 6 29 ) 4/10 – – – – 3/4
10/10 – – – 1/1 4/4
Roy Steven Herbst 10/10 – – – 1/1 4/4
10/10 5/5 2/2 3/3 – 4/4
10/10 5/5 2/2 – 1/1 4/4
2021 12 16 1/10 – 0/2 0/3 – 0/4
2021 8 30 9/10 – 2/2 3/3 – 4/4
2021 12 16
(1) 4 1 1 A H
1
80
81
171 172
3,330,000 1,658,000
3,330,000
3,330,000
1,658,000
1,050,000
608,000
4,988,000
82
2021 4 29 2021 4 29
3.29 15
10%
83
3%
3% 10
2
H
183 54
+852 2810 8185
A
100 6 7 16
200126
+86 021 6175 7377
+86 021
6105 8800
84
2021 6 29 2021 12 16
1.
2.
3. 2018
F.1.1
(1)
(2)
(3)
10%
50%
85
25%
86
2021 1 1 2021 12 31 2021
TopAlliance Biosciences, Inc. TopAlliance
87
( www.hkex.com.hk) ( www.sse.com.cn)
( www.junshipharma.com)
88
2012
2018 12
2020 7
(GMP)
GMP
TopAlliance Fc
89
2021
40.25 152.36%
2021
3
23 VV116
PARP III 25
40.25 152.36% 20.69 16.35%
JS016 Eli Lilly and Company
LY-CoV555 15
12
2021
PD-1
26
2021 9
BLA 2021
10 BLA FDA
90
2021
2021 1 2020
2021 3
2021 5 2020
TOP
2021 6 2020
BTLA
SARS-CoV-2
91
2021 6
2021 7 SMDC 2021
2021
2021 8 2020
2021 9 2021 2021
2021 20
2020 TOP30
2021 11 21 21 2021
2021 21 10
2021 21 10
92
2021 12 2021 2021
2021
2021
2021 12
2021 12 2021
93
2021
2021
14
94
(JS016)
2021
Eli Lilly and Company 15
70
3.5 1.4
2021
JS016 2021
2021
95
VV116
3 I
COVID-19 VV116
III
COVID-19 II/III
(NCT05242042)
2021 12 VV116 COVID-19
VV116
96
3CL VV993
VV116 VV993
VV993
2021 11 1 3 (ANSO)
(RIFC)
60
600
97
3060
98
17
1.
99
2.
100
3.
2021
101
1.
102
2021
2.
2021
3.
103
( www.hkex.com.hk) ( www.sse.com.cn)
( www.junshipharma.com)
4.
104
(ADCs)
1.
2021
20.69 16.35%
105
2.
2021 51
2021
2021 9 15
III JUPITER-02
26
+
106
2021 (ESMO) 11
(ESCC) JUPITER-06
ESMO JUPITER-06
PD-1
2
107
3.
2021 12 31 108 84 24
108
1.
2020 7
2020 2020 12 30
2020
2021
109
GMP
GMP 2021
FDA GMP
5 PK
110
2021
(EQS) DMS TMS QMS
LIMS
2021 9 7
111
2.
2021
112
2021
2021
113
3.
2021
SOP
2021 1
2021 2,323
98%
11
45
2,267
114
2021 8*15,000L
15,000L
2021
115
2021
116
1.
2021
79,854.55 40,820.20 37,289.90
35,535.04 8,069.64
27,465.40
47%
51%
2%
2021 411,962.40
2021 (BMS)
3060
117
2.
EHS EHS
2021
2021 4.10 (NOx)4.06
(SOx)0.04
118
2021
2021 140.50
274.80
119
3.
120
1.
2021
2021
2021 2,805
52%
121
2%
52% 48%
48%
50%
2021
2021
122
2021 IT
2021
123
124
2021
2021
GMP
125
2021 12
6 9
126
2.
2021 12
2021
12
127
PD-1
102 2021 11
11 51
2021 4
20,000 2021 11 17
94 143
80 37,000
23
128
2021
2019 4 2021 2 30 142
5,000
2021 2021
9 30 26 169 3,000
2021 12 2021
129
2020 40 2021
15
2022 1
2021 7
100
130
2022 3
4
4 PCR
82
131
2021 2
2020 2019
A1.1 1
NOX 4.06 4.96 3.82
SOX 0.04 0.004 0.002
4.10 4.96 3.82
0.001 0.003 0.005
A1.2
1 3
8,069.64 5,783.59 3,812.70
2 4
27,465.40 23,861.66 13,007.78
35,535.04 29,645.25 16,820.48
1& 2 8.83 18.59 21.70
A1.3
140.50 137.27 63.65
0.03 0.09 0.08
A1.4
5
274.80 183.00 615.00
0.07 0.11 0.79
1
(EMFAC-HK Vehicle Emission Calculation)
2
2021
3
4
5
2021 2020
132
2021 2
2020 2019
A2.1 6
40,820.20 33,918.49 18,490.09
37,289.90 27,660.00 18,227.66
1,744,45
79,854.55 61,578.49 36,717.75
19.84 38.61 47.37
A2.2
411,962.40 303,598.00 194,273.00
102.35 190.36 250.65
A2.5
9.36 17.04 10.95
16.81 14.39 9.81
26.17 31.44 20.76
0.01 0.02 0.03
6
133
2021 2020 2019
B1.1
2,805 2,453 1,421
1,343 1,230 738
1,462 1,223 683
2,805 2,453 1,357
0 0 29
0 0 35
≤30 1,337 1,144 596
30~50 1,407 1,249 759
≥50 61 60 66
2,777 2,437 1,410
28 16 11
B1.2
26.85% 24.39% 16.71%
20.33% 19.41% 18.14%
≤30 19.41% 19.66% 15.80%
30~50 27.44% 24.60% 19.61%
≥50 16.44% 11.11% 8.20%
23.73% 22.04%
6.67% 7.41%
B2.1
B2.2
250 136
134
2021 2020 2019
B3.1
80.49% 70.57% 73.58%
72.09% 70.07% 68.52%
53.07% 53.21% 38.00%
70.40% 74.51% 50.18%
79.83% 70.73% 79.89%
B3.2
36.82 27.72 72.69
30.15 26.86 68.75
14.00 15.28 35.70
12.31 18.26 49.62
41.25 30.59 80.21
135
A A1
2.
(a)
(b)
A1.1
A1.2
1 2
A1.3
A1.4
A1.5
2.
A1.6
2.
136
A2
1.
A2.1
A2.2
A2.3
1.
A2.4
1.
A2.5
137
A3
1.
2.
A3.1
1.
2.
A4
3.
A4.1
3.
B B1
1.
(a)
(b)
B1.1
B1.2
138
B2
1.
(a)
(b)
B2.1
B2.2
B2.3
1.
B3
1.
B3.1
B3.2
B4
1.
(a)
(b)
139
B4.1
1.
B4.2
1.
B5
3.
B5.1
3.
B5.2
3.
B5.3
3.
B5.4
3.
140
B6
1.
2.
(a)
(b)
B6.1
2.
B6.2
2.
B6.3
3.
B6.4
1.
2.
B6.5
2.
141
B7
1.
(a)
(b)
B7.1
1.
B7.2
1.
B7.3
1.
B8
2.
B8.1
2.
B8.2
2.
142
51
34
41 53
173 174
143
2022 2
III
JUPITER-15 NCT05180734
2022 3
NMPA
2022 3 JS105 PI3K-α IND NMPA
2022 3 JS116 KRASG12C IND NMPA
2022 1 Coherus 2021 2 Coherus
TIGIT TAB006/JS006
Coherus TAB006/JS006 TAB006/JS006 Coherus
3,500 Coherus 2.55
TAB006/JS006 Coherus 18%
2022 3 JS120
IDH1 JS121 SHP2 JS122 FGFR2 JS123
ATR
2022 3 GMP
CGMP
30,000
2022 3 7,000 A
39.8
40
144
IND
PD-1
PCSK9 BLyS BTLA
51
1
2
3
145
(i) 35.56% 2020 11.56% 46.51% 2020
34.45%
(ii) 62.80% 2020 33.45%
96.19% 2020 79.89%
5%
14
2021 12 31 34
29
2021 12 31 910,756,700 691,461,000 A 219,295,700 H
146
2021 12 31
2021 12 31 25
H
2021 6 23 J.P. Morgan Securities plc
2021 6 16
36,549,200 H
2,105
2021 6 16 2021 6 23
2021 12 31 1,411
2021 12 31
12/31/2021 12/31/2021
596 2025 6 30
– 2025 6 30
61 2025 6 30
754 2025 6 30
1,411 674
147
2018
2018 5 14 2018
2019 6 17 2018 2019
2019 H
2019 5 27 2018
2020 5 11 2019 2020
2020 H 2020 4 20
2018 3 12 268 6,023,000
2018
2018
2018
(a)
2018
2018
12
2018
148
(b) 2018
2018
(c) 2018
2022 12 14 29
(d)
2018
(e) 9.2
2018
(f) 2018
25%
12 5
35% 5
17 40%
17 29
(g)
H 2018
149
2020 8 28 2018
203 1,219,500
A 9.2 2020 11 2 2018
1,219,500 A 2021 12 31
0.13% 203 11,219,400 1,219,500
9,999,900 A
2018
2020 8 28 2020 11 2
2021 12 31 1,845,200 187 1,845,200
A 2021 12 31 0.20% 2018 3
1,246,800 A
1,246,800
2021 2021
1 1 (2)
12 31 (1)
A
7,500 – 3,500 – – 4,000 2019 3 12 9.2
2022 12 14
3,659,200 – 1,708,000 – 110,000 1,841,200 2019 3 12 9.2
2022 12 14
3,666,700 – 1,711,500 – 110,000 1,845,200
1. 25% 12
5 35%
5 17
40% 17
29
2.
150
2022 12 31 2022 12 31
A
2022 12 31
A
A
2022 12 31 1,845,200 1,845,200 0.20%
A 2018
2018
31
2018
2020 A
2020 9 29 2020 A 2020 A
2020 11 16 2020 2020 A 2020 H
2020 A
2020 A
(a) 2020 A
151
(b) 2020 11 16 2020 A
1,933 28,519,000
(c) 2020 A 2020 11
16 2020 2020 A 2020 H
12 12
(d) 2020 A 35,648,000 A
A 5.16% 3.91% 2020 A
7,129,000 A 20%
A
(e) 1%
(f) 2020 A 2020 11 16
48
(g)
(1) 40% 12
24 (2)
30% 24 36
(3) 30% 36
48
152
(1) 50% 12
24 (2)
50% 24 36
(h) A 55.50
A A
55.50
(i) 2020 A A 2020 9 29
A 50% A 85.46 (ii) 20 60
120 A 50% 20 A 90.25
A 2020 7 15 A 55.50
(i) 2020 A
(j)
153
2021 12 31 28,519,000 2020 11 16
7,129,000 2021 11 15
2020
11 16 2021
(1)
12 31 (2)
820,000 – – – 820,000 2021 11 16
(4)
2024 11 15
1,560,000 – – – 1,560,000 2021 11 16
(4)
2024 11 15
820,000 – – – 820,000 2021 11 16
(4)
2024 11 15
2,000,000 – – – 2,000,000 2021 11 16
(4)
2024 11 15
820,000 – – – 820,000 2021 11 16
(4)
2024 11 15
270,000 – – – 270,000 2021 11 16
2024 11 15
360,000 – – – 360,000 2021 11 16
2024 11 15
300,000 – – – 300,000 2021 11 16
2024 11 15
300,000 – – – 300,000 2021 11 16
2024 11 15
150,000 – – – 150,000 2021 11 16
2024 11 15
80,000 – – – 80,000 2021 11 16
2024 11 15
80,000 – – – 80,000 2021 11 16
2024 11 15
80,000 – – – 80,000 2021 11 16
2024 11 15
154
2020
11 16 2021
(1)
12 31 (2)
30,000 – – – 30,000 2021 11 16
(5)
2024 11 15
20,849,000 – 4,273,700 – 16,575,300 2021 11 16
2024 11 15
1,919
28,519,000 – 4,273,700 – 24,245,300 2021 11 16
2024 11 15
(1) 2020 11 16
(2) (1) 40% 12
24 (2) 30%
24 36 (3)
30% 36 48
(3) A 55.50
(4) 14A
(5) 14A
(6)
155
2021
11 15 2021
(1)
12 31 (2)
7,129,000 – – – 7,129,000 2022 11 15
880 2024 11 14
7,129,000 – – – 7,129,000
(1) 2021 11 15
(2) (1) 50% 12
24 (2) 50%
24 36
(3) A 55.50
(4)
31
2020 A 2020 10 22
2020 11 16 2021 11 15
156
2020 A
2021 11 2
2021 6 29
Roy Steven Herbst
2021 12 16
2021 8 30 2021 12 16
157
2021 6 29
2021 6 29
2021 6 29
2021 6 29
13.51B(1)
2020 13.51B(1)
2021 3 31
2020 3 23
2021 4 30
2015 11 20
2021 5 19
2020 5 12
2021 8 6
2021 12 31
2021 12 31
2021 9 24
2021 9 24
158
3.13
3.13
12
159
2021 12 31
XV XV 7 8
352
(1) (1) (1)
(2)
A 88,574,018 (L) 12.81% 9.73%
H 2,600 (L) 0.00% 0.00%
(2)
A 129,978,568 (L) 18.80% 14.27%
(3)
A 1,560,000 (L) 0.23% 0.17%
A 3,657,600 (L) 0.53% 0.40%
(4)
A 13,960,000 (L) 2.02% 1.53%
(5)
A 9,428,000 (L) 1.36% 1.04%
(6)
A 2,000,000 (L) 0.29% 0.22%
A 7,774,500 (L) 1.12% 0.85%
(7)
A 196,871,786 (L) 28.47% 21.62%
H 2,600 (L) 0.00% 0.00%
(8)
A 78,852,000 (L) 11.40% 8.66%
H 37,189,000 (L) 16.96% 4.08%
(8)
160
1. L S P 2021 12 31
910,756,700 691,461,000 A 219,295,700 H
2. 2021 12 31 88,574,018 A 2,600 H 2020 A
820,000
(i)
2017 12 25 2017 2021 12
31 2017 108,297,768 A
41,060,000 A (ii)
2019 7 26 2019 2021 12 31
2019 21,680,800 A
2021 12 31 (i) 20%
4,372,144 A 2017 (ii)
40%
4,600,000 43,584,000 A 2017
86.28% 52,556,144 A
3. 2021 12 31 2020 A 1,560,000
4. 2021 12 31 13,140,000 A 2020 A 820,000
5. 2021 12 31 8,608,000 A 2020 A
820,000
6. 2021 12 31 2020 A 2,000,000
7. 2021 12 31 7,774,500 A 60%
86.28%
2017
161
8. 2021 12 31 76,590,000 A
2,262,000 A
99.99%
2021 12 31 Loyal Valley Capital Advantage Fund LP LVC Fund I Loyal Valley Capital Advantage Fund
II LP LVC Fund II LVC Renaissance Fund LP LVC Renaissance Fund LVC Fund I LVC Fund II
LVC Funds 10,106,000 H 12,127,000 H 14,956,000 H Loyal Valley Capital
Advantage Fund GP Limited LVC Fund I GP LVC Fund I Loyal Valley Capital Advantage Fund
II Limited LVC Fund II GP LVC Fund II LVC Renaissance Limited LVC Renaissance GP
LVC Renaissance Fund LVC Fund I GP LVC Fund II GP LVC Renaissance GP LVC Holdings
Limited LVC Innovate Limited LVC Bytes Limited Jovial Champion
Investments Limited Jovial Champion Investments Limited Vistra Trust (Singapore)
Pte. Limited LVC Renaissance Fund(i) Golden Valley Global Limited 20.13%
99.99%
(ii) Loyal Valley Innovation Capital (HK) Limited
33.28% LVC Funds
37,189,000 H
2021 12 31
XV
352
XV
162
2021 12 31
XV 2 3
336
(1) (2) (2)
(3) (4)
A 41,060,000 (L) 5.94% 4.51%
A 155,811,786 (L) 22.53% 17.11%
A 43,584,000 (L) 6.30% 4.79%
(4)
A 153,287,786 (L) 22.17% 16.83%
A 4,600,000 (L) 0.67% 0.51%
(4)
A 192,271,786 (L) 27.81% 21.11%
(4)
A 4,372,144 (L) 0.63% 0.48%
A 192,499,642 (L) 27.84% 21.14%
(4)
A 4,288,400 (L) 0.62% 0.47%
A 192,583,386 (L) 27.85% 21.15%
(4)
A 3,789,720 (L) 0.55% 0.42%
A 193,082,066 (L) 27.92% 21.20%
(4)
A 3,719,504 (L) 0.54% 0.41%
A 193,152,282(L) 27.93% 21.21%
(4)
A 2,884,000 (L) 0.42% 0.32%
A 193,987,786 (L) 28.05% 21.30%
(5)
A 21,680,800 (L) 3.14% 2.38%
A 88,574,018 (L) 12.81% 9.73%
(6)
A 76,590,000 (L) 11.08% 8.41%
(6)
A 76,590,000 (L) 11.08% 8.41%
(6)
A 76,590,000 (L) 11.08% 8.41%
(6)
A 78,852,000 (L) 11.40% 8.66%
163
(1) (2) (2)
A 78,852,000 (L) 11.40% 8.66%
(6)(8)
(7)(8)
H 37,189,000 (L) 16.96% 4.08%
Loyal Valley Capital Advantage H 10,106,000 (L) 4.61% 1.11%
Fund LP(7)(9)
Loyal Valley Capital Advantage H 10,106,000 (L) 4.61% 1.11%
Fund GP Limited (7)
Loyal Valley Capital Advantage H 12,127,000 (L) 5.53% 1.33%
Fund II LP(7)(9)
Loyal Valley Capital Advantage H 12,127,000 (L) 5.53% 1.33%
Fund II Limited (7)
LVC Renaissance Fund LP(7) H 14,956,000 (L) 6.82% 1.64%
LVC Renaissance Limited(7) H 14,956,000 (L) 6.82% 1.64%
LVC Holdings Limited (7)
H 22,233,000 (L) 10.14% 2.44%
LVC Management Holdings Limited (7)
H 22,233,000 (L) 10.14% 2.44%
LVC Bytes Limited LVC H 37,189,000 (L) 16.96% 4.08%
Innovate Limited)(7)
Jovial Champion Investments Limited(7) H 37,189,000 (L) 16.96% 4.08%
Vistra Trust (Singapore) Pte. Limited (7)
H 37,189,000 (L) 16.96% 4.08%
Highbury Investment Pte Ltd (9)
H 12,218,889 (L) 5.57% 1.34%
H 12,127,000 (L) 5.53% 1.33%
GIC (Ventures) Pte. Ltd. (9)
H 24,345,889 (L) 11.10% 2.67%
GIC Special Investments Private Limited (9)
H 24,345,889 (L) 11.10% 2.67%
GIC Private Limited (9)
H 24,345,889 (L) 11.10% 2.67%
H 715,511(L) 0.33% 0.08%
Hillhouse Capital Advisors, Ltd. (10)
H 11,400,000 (L) 5.20% 1.25%
1. L S P
2. 2021 12 31 910,756,700 691,461,000 A 219,295,700 H
164
3. 2021 12 31 41,060,000 A 2017
2017 155,811,786 A
88,574,018 A 2020 A 820,000
4. 2017 2017
A
5. 2019 2019
6. 2021 12 31 76,590,000 A
99.99%
76,590,000 A
2,262,000 A A
7. 2021 12 31 Loyal Valley Capital Advantage Fund LP LVC Fund I Loyal Valley Capital Advantage
FundII LP LVC Fund II LVC Renaissance Fund LP LVC Renaissance Fund LVC Fund I LVC Fund II
LVC Funds 10,106,000 H 12,127,000 H 14,956,000 H Loyal Valley Capital
Advantage Fund GP Limited LVC Fund I GP LVC Fund I H
Loyal Valley Capital Advantage Fund II Limited LVC Fund II GP LVC Fund II
H LVC Renaissance Limited LVC Renaissance GP LVC Renaissance Fund
H
LVC Fund I GP LVC Fund II GP LVC Holdings Limited LVC Management Holdings
Limited LVC Holdings Limited LVC Management Holdings Limited LVC Fund I
LVC Fund II H
LVC Fund I GP LVC Fund II GP LVC Renaissance GP LVC Innovate Limited LVC Bytes Limited
LVC Innovate Limited Jovial Champion Investments Limited Vistra Trust
(Singapore) Pte. Limited LVC Innovate Limited LVC Bytes Limited
Jovial Champion Investments Limited Vistra Trust (Singapore) Pte. Limited LVC Funds H
8. 2021 12 31
76,590,000 A
2,262,000 A
9. 2021 12 31 Highbury Investment Pte Ltd Highbury 12,218,889 H Highbury LVC
Fund II 90.90% LVC Fund II 12,127,000 H Highbury GIC (Ventures) Pte.
Ltd. GIC Ventures GIC Special Investments Private Limited GIC SIPL
GIC Private Limited GIC Private GIC Ventures GIC SIPL GIC Private
Highbury H
10. 2021 12 31 Hillhouse Capital Advisors, Ltd. Gaoling Fund, L.P. YHG Investment, L.P.
Gaoling Fund, L.P. YHG Investment, L.P. 10,715,000 H 685,000 H
165
H 2021 6 23 36,549,200 H
2021 6 15 2018
1,711,500 A
2019 5 27 2020 4 20 2018
2020 12 17 2021 6 15
14A
14A
33
33 14A.76 14A.95
14A
36
166
H
20%
20%
H
[2008]897 H 2008 10%
2021 H
167
69 85
86 141
8.08(1)
H
(a) 16%
(b) H
(c) H
2018 A
(i) 18A.07 H
375 (ii)
15.71%
12
168
2021 12 31
2021 12 31
H
H
2022 3 31
*
169
173 279
2021 12 31
2021 12 31
170
2021 12
31 2,068,739,000
24 2021 12 31
227,709,000
171
172
2022 3 31
173
2021 12 31
12 31
2021 2020
5 4,024,841 1,594,897
(1,258,187) (372,531)
2,766,654 1,222,366
6 123,762 77,454
7 74,237 27,591
342 (255)
(2,068,739) (1,778,023)
(734,563) (687,971)
(647,950) (443,346)
35 (1)
(48,498) (3,804)
(36,095) (54,081)
8 (21,833) (29,391)
9 (592,648) (1,669,461)
10 (135,533) 3,822
(728,181) (1,665,639)
19,454 –
(9,852) (21,928)
9,602 (21,928)
(718,579) (1,687,567)
174
2021 12 31
12 31
2021 2020
(718,557) (1,665,639)
(9,624) –
(728,181) (1,665,639)
(708,955) (1,687,567)
(9,624) –
(718,579) (1,687,567)
11
(0.80) (2.02)
(0.80) (2.02)
175
2021 12 31
12 31
2021 2020
14 2,727,809 2,348,155
15 341,983 186,239
16 40,251 31,019
17 16,056 1,021
18 441,736 65,150
28 88,550 26,113
21 533,914 297,725
22 1,027,108 356,725
23 1,574 –
5,218,981 3,312,147
19 484,601 343,425
20 1,292,933 663,323
21 549,141 306,954
22 – 17
23 459 –
23 3,504,605 3,384,998
5,831,739 4,698,717
24 1,907,523 1,215,016
25 10,596 252,346
26 3,683 –
27 34,472 25,220
60,361 –
2,016,635 1,492,582
3,815,104 3,206,135
9,034,085 6,518,282
176
2021 12 31
12 31
2021 2020
25 490,000 542,222
26 118,776 103,809
27 93,127 30,991
701,903 677,022
8,332,182 5,841,260
29 910,757 872,496
7,050,146 4,968,767
7,960,903 5,841,263
371,279 (3)
8,332,182 5,841,260
173 279 2022 3 31
177
2021 12 31
2020 1 1 784,147 4,143,394 – 37,338 – – 12,535 (1,988,895) 2,988,519 (3) 2,988,516
– – – – – – – (1,665,639) (1,665,639) – (1,665,639)
– – – – – – (21,928) – (21,928) – (21,928)
– – – – – – (21,928) (1,665,639) (1,687,567) – (1,687,567)
A
29 87,130 4,748,585 – – – – – – 4,835,715 – 4,835,715
A – (338,737) – – – – – – (338,737) – (338,737)
-
31 – – – 6,549 – – – – 6,549 – 6,549
1,219 21,110 – (11,110) – – – – 11,219 – 11,219
31 – – 25,565 – – – – – 25,565 – 25,565
2020 12 31 872,496 8,574,352 25,565 32,777 – – (9,393) (3,654,534) 5,841,263 (3) 5,841,260
– – – – – – – (718,557) (718,557) (9,624) (728,181)
– – – – – 19,454 – – 19,454 – 19,454
– – – – – – (9,852) – (9,852) – (9,852)
– – – – – 19,454 (9,852) (718,557) (708,955) (9,624) (718,579)
178
2021 12 31
H 36,549 2,097,832 – – – – – – 2,134,381 – 2,134,381
H – (30,434) – – – – – – (30,434) – (30,434)
– – – – 514,094 – – – 514,094 380,906 895,000
31 – – – 2,499 – – – – 2,499 – 2,499
31 – – 192,309 – – – – – 192,309 – 192,309
1,712 30,242 – (16,208) – – – – 15,746 – 15,746
2021 12 31 910,757 10,671,992 217,874 19,068 514,094 19,454 (19,245) (4,373,091) 7,960,903 371,279 8,332,182
2021 12 16
A 12.75 A
68.125% 31.875% 2021 12 31 A 8.95
2022 3 25 3.8
179
2021 12 31
12 31
2021 2020
(592,648) (1,669,461)
(30,979) (20,278)
21,833 29,391
(2,830) (1,798)
16,198 31,222
(114,208) (43,594)
– (630)
215,825 120,581
41,469 28,745
5,265 2,036
(342) 255
13,647 4,227
34 734
192,754 30,728
(35) 1
48,498 3,804
(185,519) (1,484,037)
(154,823) (166,986)
(629,062) (512,646)
(250,010) (3,660)
734,292 658,446
(19,170) 11,778
(504,292) (1,497,105)
(137,609) (1,701)
(641,901) (1,498,806)
180
2021 12 31
12 31
2021 2020
30,979 20,278
(772,346) (560,581)
11 –
(14,497) (26,718)
(99,385) (5,383)
(19,774) (3,552)
3,663 851
(2,033) –
– 6,828
(15,000) –
18 (425,084) –
– 2,900
(1,169,620) (175,137)
565,284 106
1,176 9,443
– (70,029)
– 70,029
(4,976) (4,520)
40,650 37,509
(1,880,952) (697,976)
181
2021 12 31
12 31
2021 2020
H 2,134,381 –
H (29,677) –
A – 4,835,715
A – (337,730)
500,000 374,239
(793,333) (401,416)
(22,472) (46,236)
(33,959) (22,269)
895,000 –
15,746 11,219
2,665,686 4,413,522
142,833 2,216,740
3,384,998 1,214,026
(23,226) (45,768)
3,504,605 3,384,998
182
2021 12 31
1.
2012 12 27
2015 5 2015 8
833330) 2018 12 24 H
1877) 2020 5 8
2020 7 15 A 688180)
2.
2021 1 1
9 2
39
7
4
16
2021 6
183
2021 12 31
2.
17 3
3 2
10
28 4
16 2021 6 30 1
1 3
1 3
2
8 3
12 3
16 2
37 2
2018 2020 2
1
2021 4 1
2
2022 1 1
3
2023 1 1
4
184
2021 12 31
2.
1
12
(i) 12
(ii)
32
2021 12 31
1 2
1
185
2021 12 31
2.
1 2
2
8
8
3.
3.1
186
2021 12 31
3.
3.1
2 16
2 36
187
2021 12 31
3.
3.2
188
2021 12 31
3.
3.2
189
2021 12 31
3.
3.2
9
28
36
36
190
2021 12 31
3.
3.2
9
191
2021 12 31
3.
3.2
(a)
192
2021 12 31
3.
3.2
(b)
(c)
193
2021 12 31
3.
3.2
16
194
2021 12 31
3.
3.2
12
195
2021 12 31
3.
3.2
9
196
2021 12 31
3.
3.2
197
2021 12 31
3.
3.2
2021 6 30
16
198
2021 12 31
3.
3.2
199
2021 12 31
3.
3.2
200
2021 12 31
3.
3.2
12
201
2021 12 31
3.
3.2
202
2021 12 31
3.
3.2
203
2021 12 31
3.
3.2
204
2021 12 31
3.
3.2
205
2021 12 31
3.
3.2
15
3
206
2021 12 31
3.
3.2
(i)
(ii)
207
2021 12 31
3.
3.2
(iii)
9
9
(i)
208
2021 12 31
3.
3.2
9
(i)
30
(ii)
90
209
2021 12 31
3.
3.2
9
(iii)
(iv)
(v)
210
2021 12 31
3.
3.2
(v)
211
2021 12 31
3.
3.2
212
2021 12 31
4.
3
2021 12 31
88,550,000 2020 26,113,000
451,455,000 2020 386,314,000
3,998,929,000 2020 3,529,965,000
213
2021 12 31
4.
2021 12 31
568,737,000 2020 172,127,000
36b
5.
2021 2020
426,636 1,102,278
3,341,118 405,103
1,066 87,516
3,768,820 1,594,897
256,021 –
4,024,841 1,594,897
214
2021 12 31
5.
60 2020 35 65
15
2021 12 31 Coherus BioSciences, Inc
Coherus
2020 12 31
2021 12 31 Coherus Coherus
Coherus
290,000,000
2021 12 31 975,150,000 2020 70,956,000
1,254,234,000 2020 334,147,000 1,111,734,000
2020 960,000,000
45 60 2020
60
215
2021 12 31
5.
15
12 31
2021 2020
427,312 1,003,464
3,597,529 591,433
4,024,841 1,594,897
12 31
2021 2020
4,037,989 2,902,608
35,385 13,947
4,073,374 2,916,555
216
2021 12 31
5.
10%
12 31
2021 2020
1
2,366,358 591,433
Coherus 2
1,231,171 –
1
2
6.
12 31
2021 2020
30,979 20,278
a 2,830 1,798
b 89,061 16,758
c – 38,504
892 116
123,762 77,454
(a)
(b)
(c)
217
2021 12 31
7.
12 31
2021 2020
114,208 43,594
– 630
(34) (734)
(39,937) (11,672)
– (4,227)
74,237 27,591
8.
12 31
2021 2020
16,053 43,115
– (16,803)
16,053 26,312
5,780 3,079
21,833 29,391
2020 5.23%
218
2021 12 31
9.
12 31
2021 2020
3,330 3,080
5,265 2,036
44,964 32,240
(3,495) (3,495)
41,469 28,745
224,834 133,583
(9,009) (13,002)
215,825 120,581
25,734 52,979
13,647,000
2020 4,227,000
135,976 151,942
473,595 310,623
1,014,026 860,104
120,479 28,152
194,808 32,114
(12,093) (27,357)
(82,113) (53,046)
1,235,107 839,967
219
2021 12 31
10.
12 31
2021 2020
– 1,695
197,970 –
– 6
197,970 1,701
28 (62,437) (5,523)
135,533 (3,822)
25%
2020 11
18 2021 11 30 2021 12 23
2020 2022 2021 2023 2021 2023
15%
15%
21%
2021 12 31
8.84% 2020 8.84%)
2021 12 31
197,970,000 2020 2021 12 31 6% 10%
220
2021 12 31
10.
12 31
2021 2020
(592,648) (1,669,461)
25% 2020 25%) (148,162) (417,365)
(9) –
12,124 951
(28,233) –
106,849 61,051
(176,789) (138,825)
41,943 87,179
(25,658) –
– 6
119,262 391,851
36,236 11,330
197,970 –
135,533 (3,822)
[2018]99 2021 12 31 2020 12 31
175% 2020 175%
200% 2020 175%
221
2021 12 31
11.
(a)
12 31
2021 2020
(718,557) (1,665,639)
12 31
2021 2020
892,659,689 824,816,637
(b)
31 2018 5 14 2020 11 16 2021 11 15
2021 12 31 2020 12 31
222
2021 12 31
12.
l
2021 12 31
– 7,288 18,748 – 26,036 12,333 38,369
– 3,873 1,205 115 5,193 6,483 11,676
– 3,527 645 67 4,239 6,483 10,722
– 3,526 1,096 115 4,737 6,483 11,220
– 3,807 645 – 4,452 15,811 20,263
a – 350 – – 350 – 350
b – 2,205 – – 2,205 – 2,205
– – – – – – –
a – – – – – – –
c – – – – – – –
– – – – – –
– – – – – – –
– – – – – – –
d – 130 – 42 172 – 172
e – 118 120 28 266 – 266
e – – – – – – –
e – 508 118 9 635 – 635
5,160 – – – 5,160 – 5,160
f – – – – – – –
200 – – – 200 – 200
Roy Steven Herbst 1,935 – – – 1,935 – 1,935
g 480 – – – 480 – 480
200 – – – 200 – 200
7,975 25,332 22,577 376 56,260 47,593 103,853
223
2021 12 31
12.
l
2020 12 31
– 7,637 17,990 18 25,645 1,415 27,060
– 4,966 2,541 67 7,574 744 8,318
– 3,046 1,350 27 4,423 744 5,167
– 3,757 1,401 68 5,226 744 5,970
– 3,106 1,350 – 4,456 1,814 6,270
b – 2,015 33,415 – 35,430 – 35,430
– – – – – – –
– – – – – – –
– – – – – – –
– – – – – – –
b – – – – – – –
– – – – – – –
– – – – – – –
h – 197 250 17 464 – 464
– 240 199 30 469 – 469
– – – – – – –
– 211 – – 211 – 211
5,431 – – – 5,431 – 5,431
i 118 – – – 118 – 118
j – – – – – – –
200 – – – 200 – 200
Roy Steven Herbst 2,025 – – – 2,025 – 2,025
g 42 – – – 42 – 42
k 106 – – – 106 – 106
7,922 25,175 58,496 227 91,820 5,461 97,281
224
2021 12 31
12.
(a) 2021 11
(b) 2020 10 2020 12 31
2021 12 31
(c) 2021 6
(d) 2021 6
(e) 2021 6 2021 12 31
(f) 2021 12
(g) 2020 11 2021 8 2021 12
(h) 2020 11
(i) 2020 6
(j) 2020 11
(k) 2020 6
(l) 2021 2020 12 31
225
2021 12 31
12.
2020
2020
12 31
2021 2020
3,354 1,811
2,580 5,900
– 34
7,906 –
13,840 7,745
12 31
2021 2020
7,000,001 7,500,000 – 1
8,500,001 9,000,000 – 1
9,500,001 10,000,000 – 1
13,500,001 14,000,000 1 –
14,000,001 14,500,000 1 –
16,500,001 17,000,000 1 –
24,000,001 24,500,000 1 –
31,000,001 31,500,000 – 1
40,500,001 41,000,000 – 1
46,000,001 46,500,000 1 –
13.
2021 2020 12 31
226
2021 12 31
14.
2020 1 1 79,028 210,508 109,780 28,145 14,197 1,490,193 1,931,851
102,635 6,038 38,644 1,029 12,338 493,866 654,550
704,785 699,860 156,842 5,224 – (1,566,711) –
– (2,133) (670) – – – (2,803)
– – 161 – – – 161
2020 12 31 886,448 914,273 304,757 34,398 26,535 417,348 2,583,759
2,445 1,015 60,286 4,148 30,489 509,505 607,888
13,168 45,135 63,436 – – (121,739) –
(2,986) (10) (950) – – – (3,946)
– – (63) – – – (63)
2021 12 31 899,075 960,413 427,592 38,546 57,024 805,114 3,187,764
2020 1 1 6,900 46,086 34,731 11,303 4,963 – 103,983
28,085 57,829 34,260 5,073 8,336 – 133,583
– (1,622) (447) – – – (2,069)
– – 107 – – – 107
2020 12 31 34,985 102,293 68,651 16,376 13,299 – 235,604
42,494 88,619 71,787 6,001 15,933 – 224,834
(162) (10) (328) – – – (500)
– – 17 – – – 17
2021 12 31 77,317 190,902 140,127 22,377 29,232 – 459,955
2021 12 31 821,758 769,511 287,465 16,169 27,792 805,114 2,727,809
2020 12 31 851,463 811,980 236,106 18,022 13,236 417,348 2,348,155
227
2021 12 31
14.
4.75%
9.50% – 31.67%
19.00% – 31.67%
19.00% – 31.67%
33.33% – 50.00%
2021 12 31 664,538,000 2020 1,716,673,000
25
93,243,000 2020 96,491,000
15.
2021 12 31
224,729 117,254 341,983
2020 12 31
131,069 55,170 186,239
2021 12 31
5,725 39,239 44,964
2020 12 31
5,559 26,681 32,240
228
2021 12 31
15.
12 31
2021 2020
4,233 7,441
248 151
143,605 38,323
200,708 38,961
20 50
2020
2021 2020 12 31
2021 12 31 55,611,000 2020 58,862,000
25
2021 12 31 2020
1 3 37,280,000
27 36b
229
2021 12 31
16.
2020 1 1 7,539 – – 7,539
6,855 19,811 98 26,764
2020 12 31 14,394 19,811 98 34,303
14,497 – – 14,497
2021 12 31 28,891 19,811 98 48,800
2020 1 1 1,248 – – 1,248
2,029 – 7 2,036
2020 12 31 3,277 – 7 3,284
5,253 – 12 5,265
2021 12 31 8,530 – 19 8,549
2021 12 31 20,361 19,811 79 40,251
2020 12 31 11,117 19,811 91 31,019
20% – 50%
10%
2020 8 28
19,811,000
230
2021 12 31
17.
12 31
2021 2020
16,000 1,000
56 21
16,056 1,021
2021 2020 2021 2020
12 31 12 31 12 31 12 31
50% 50% 50% 50%
50% 50% 50% 50%
231
2021 12 31
17.
12 31
2021 2020
35 (1)
16,056 1,021
18.
2021 4 30 20,000,000
50% 2021 7 19 50,000,000
50%
Anwita
355,084,000
12 31
2021 2020
495,930 70,846
(50,857) (5,203)
(3,337) (493)
441,736 65,150
232
2021 12 31
18.
2021 2020 2021 2020
12 31 12 31 12 31 12 31
Anwita 19.53% 20% 19.53% 20%
50% 50% 50% 50%
JPYP
50% 50% 50% 50%
50% 50%
50% 50%
233
2021 12 31
18.
Anwita
12 31
2021 2020
180,318 47,815
38,410 13,159
(51,957) (7,466)
(412) (343)
2021 2020
12 31 12 31
40,077 14,176
(15,189) (18,602)
234
2021 12 31
18.
Anwita
12 31
2021 2020
Anwita 166,359 53,165
Anwita 19.53% 20%
Anwita 32,490 10,633
75,115 55,010
(3,337) (493)
Anwita 104,268 65,150
Anwita
JPYP
12 31
2021 2020
153,865 –
429,646 –
(63,931) –
235
2021 12 31
18.
JPYP
2021 2020
12 31 12 31
– –
(77,188) –
(80,422) –
12 31
2021 2020
JPYP 519,580 –
JPYP 50% N/A
JPYP 259,790 –
JPYP 259,790 –
JPYP
236
2021 12 31
18.
2021 2020
12 31 12 31
(5,322) –
77,678 –
19.
12 31
2021 2020
353,059 277,288
102,665 31,887
28,877 34,250
484,601 343,425
237
2021 12 31
20.
12 31
2021 2020
1,285,243 589,207
7,690 74,116
1,292,933 663,323
– –
1,292,933 663,323
2020 1 1 157,416,000
12 31
2021 2020
0 – 30 1,285,217 573,437
31 – 90 26 27,876
91 – 180 – 61,103
180 7,690 907
1,292,933 663,323
2021 12 31 2020 12 31
61,583,000 90
2021 12 31 7,690,000
2020 74,116,000
36
238
2021 12 31
21.
12 31
2021 2020
13,780 24,523
16,796 12,754
a 397,383 265,524
b 351,534 130,674
c
4,976 1,176
d
7,719 2,715
11,579 –
e
125,873 13,948
154,005 154,297
1,083,645 605,611
(590) (932)
1,083,055 604,679
549,141 306,954
533,914 297,725
1,083,055 604,679
239
2021 12 31
21.
(a)
(b)
(c)
(d) 2016 12 13,574,000
2020 12 31 80% 10,859,000 20% 2,715,000
2021 12 31 20% 2,715,000
2021 11 19,298,000
40% 7,719,000
60% 11,579,000
7,719,000 2020 2,715,000 2021
12 31
(e) 2021 12 31 125,783,000 2020
13,948,000
154,005,000 2020 154,297,000
2021 12 31
36
240
2021 12 31
22.
12 31
2021 2020
– 17
a 155,218 77,030
b 46,664 133,007
c 551,651 146,688
d 20,000 –
773,533 356,725
e 253,575 –
1,027,108 356,725
(a)
(b)
(c)
78,569,000 2020 68,199,000
(d) 20,000,000 4,687,301
3
(e) Coherus
241
2021 12 31
23.
459,000
1,574,000 2022 1 2023 9
2021 12 31 0.0001% 3.66% 2020 0.01% 3.30%)
36
24.
12 31
2021 2020
196,205 90,706
89,874 106,018
a 227,709 215,933
64,569 31,656
54,149 48,330
b 932,509 210,552
c 15,742 30,149
– 64,354
213,777 205,026
20,579 19,620
d – 68,199
– 32,625
H 757 –
91,653 91,848
1,907,523 1,215,016
242
2021 12 31
24.
8,400,000
1,224,000 2020 Anwita
15 60 2020 15 60
12 31
2021 2020
0 – 30 143,117 74,433
31 – 60 32,625 4,316
61 – 180 13,473 2,009
180 6,990 9,948
196,205 90,706
(a)
(b) 5
30
(c)
(d) 22
243
2021 12 31
25.
12 31
2021 2020
500,596 774,568
– 20,000
500,596 794,568
10,596 252,346
30,000 542,222
220,000 –
240,000 –
500,596 794,568
(10,596) (252,346)
490,000 542,222
2021 2020 12 31
12 31
2021 2020
3.90% 5.23%
2021 2020
664,538 1,716,673
55,611 58,862
720,149 1,775,535
244
2021 12 31
26.
12 31
2021 2020
a 109,326 71,506
b 13,133 32,303
122,459 103,809
3,683 –
118,776 103,809
(a)
(b)
27.
12 31
2021 2020
34,472 25,220
34,031 16,942
59,096 14,049
127,599 56,211
12 (34,472) (25,220)
12 93,127 30,991
5.22% 2020 5.22%)
245
2021 12 31
28.
12 31
2021 2020
88,550 26,113
2020 1 1 27 – 939 19,624 20,590
(21) 468 (117) 5,193 5,523
2020 12 31 6 468 822 24,817 26,113
23 2,099 1,388 58,927 62,437
2021 12 31 29 2,567 2,210 83,744 88,550
246
2021 12 31
28.
2021 12 31 483,490,000 2020 392,746,000
4,557,225,000 2020 3,691,921,000
2021 12 31 32,035,000 2020
6,432,000 558,296,000 2020 161,956,000
12 31
2021 2020
225,816 304,327
205,846 39,207
14,132 35,720
3,998,929 3,529,965
5,661 7,060
4,450,384 3,916,279
3,921,172,000 2020 3,482,986,000
77,757,000 2020
46,979,000 2021 2020 12 31
247
2021 12 31
29.
1.0
2020 1 1 784,146,500 784,147
A a 87,130,000 87,130
31 1,219,500 1,219
2020 12 31 872,496,000 872,496
H b 36,549,200 36,549
31 1,711,500 1,712
2021 12 31 910,756,700 910,757
(a) 2020 7 15 55.50 87,130,000 A
4,835,715,000 87,130,000
4,748,585,000 A
(b) 2021 6 23 70.18
58.39 36,549,200 H 2,565,023,000
2,134,381,000 36,549,000
2,097,832,000
248
2021 12 31
30.
12 31
2021 2020
472,493 387,582
– 15,000
192,000 125,000
192,000 140,000
31.
2018 3 12
6,023,000 9.2 2018 5
14
2018 3 12 12 25%
2018 3 12 24 35%
2018 3 12 36 40%
249
2021 12 31
31.
2019 12 31 2020 5
11
9 4
2021 12 31 1,845,200 2020 3,666,700)
0.21% 2020 0.42%)
2021 12 31
2021
2021 12 31
1 1
2018 5 14 9.20 2020 12 16 2021 12 15 1,711,500 – (1,711,500) – –
2018 5 14 9.20 2021 12 16 2022 12 15 1,955,200 – – (110,000) 1,845,200
3,666,700 – (1,711,500) (110,000) 1,845,200
1,845,200
– 9.20 9.20 9.20
250
2021 12 31
31.
2020 12 31
2020 2020
1 1 12 31
2018 5 14 9.20 2019 3 12 2019 3 12 2020 3 12 2020 12 15 1,303,250 – (1,219,500) (83,750) –
2018 5 14 9.20 2020 3 12 2020 12 16 2021 3 12 2021 12 15 1,824,550 – – (113,050) 1,711,500
2018 5 14 9.20 2021 3 12 2021 12 16 2022 3 12 2022 12 15 2,085,200 – – (130,000) 1,955,200
5,213,000 – (1,219,500) (326,800) 3,666,700
1,711,500
– 9.20 9.20 9.20
A 83.99 2020 77.83
2021 12 31 2,461,000 2020
6,158,000 38,000 2020 391,000
251
2021 12 31
31.
A
2020 11 16
A A
A 28,519,000
2020 11 16 12 40%
2020 11 16 24 30%
2020 11 16 36 30%
A
2021 12 31
2021 2021
1 1 12 31
2020 11 16 2021 11 16 2022 11 16 11,407,600 – – 11,407,600
2020 11 16 2022 11 16 2023 11 16 8,555,700 – (2,136,850) 6,418,850
2020 11 16 2023 11 16 2024 11 16 8,555,700 – (2,136,850) 6,418,850
28,519,000 – (4,273,700) 24,245,300
252
2021 12 31
31.
A
2020 12 31
2020 2020
1 1 12 31
2020 11 16 2021 11 16 2022 11 16 – 11,407,600 – 11,407,600
2020 11 16 2022 11 16 2023 11 16 – 8,555,700 – 8,555,700
2020 11 16 2023 11 16 2024 11 16 – 8,555,700 – 8,555,700
– 28,519,000 – 28,519,000
2021 12 31 184,785,000 2020
24,570,000 2,016,000 2020 995,000
A
2021 11 15
A A
A 7,129,000
2021 11 15 12 50%
2021 11 15 24 50%
A
253
2021 12 31
31.
A
2021 12 31
2021 2021
1 1 12 31
2021 11 15 2022 11 16 2023 11 15 – 3,564,500 – 3,564,500
2021 11 15 2023 11 16 2024 11 15 – 3,564,500 – 3,564,500
– 7,129,000 – 7,129,000
2021 12 31 5,508,000
32.
50
4% 2%
2021 12 31
118,839,000 2020 26,895,000
1,640,000 2020 1,257,000
254
2021 12 31
33.
(a)
12 31
2021 2020
23,026 –
Anwita 24,627 13,156
47,653 13,156
(b)
12 31
2021 2020
3,743 –
(c)
12 31
2021 2020
JPYP – 159
255
2021 12 31
33.
(d)
12 31
2021 2020
82,123 115,029
63,363 6,928
807 518
146,293 122,475
256
2021 12 31
34.
2021 2020 12 31
2021 2020
12 31 12 31
Shanghai Junshi Biotechnology Co., Ltd.* 1,000,000,000 100% 100%
2016 6 29 1,000,000,000
Jiangsu Union Biopharm 60,000,000 100% 100%
Pharmaceutical Technology Co., Ltd.* 2013 4 1 45,000,000
Suzhou Junmeng Biopharm Co., Ltd.* 600,000,000 100% 100%
2013 10 12 600,000,000
Taizhou Junshi Biosciences Co., Ltd.* 5,000,000 100% 100%
2014 5 9
Suzhou Union Biopharm Co., Ltd.* 750,000,000 100% 100%
2013 10 12 725,600,000
Suzhou TopAlliance Biosciences Co., Ltd.* 500,000,000 100% 100%
2017 7 26 169,169,000
Junshi Hong Kong Limited 10,000,000 1 100% 100%
2019 4 23
257
2021 12 31
34.
2021 2020
12 31 12 31
TopAlliance Biosciences Inc. 95,000,000 100% 100%
2013 3 6 605,692,000
77,700,000
506,983,000
Junshi Venture Capital (Hainan) Co., Ltd.* 10,000,000 100% –
2021 6 12 3,000,000
Junshi Biomedical Technology (Hainan) 50,000,000 100% –
Investment Management Co., Ltd. * 2021 9 24 50,000,000
Shanghai JunTop Biosciences Co., Ltd.* 440,367,000 68.125% –
2021 8 6 398,532,000
Beijing Union Biopharm Junshi 25,000,000 100% 100%
Biosciences Co., Ltd.* 2016 6 12 11,200,000
258
2021 12 31
34.
2021 2020
12 31 12 31
Suzhou Junao Medicine Co., Ltd.* 420,000,000 100% 100%
2018 1 10 48,442,000
Suzhou Junshi Biotechnology Co., Ltd.* 200,000,000 100% 100%
2018 6 19 76,160,000
Suzhou Junyou Hospital 50,000,000 100% 100%
Management Co., Ltd.* 2020 11 17
Juntop Biomedical Technology 30,000,000 68.125% –
(Hainan) Co., Ltd.* 2021 12 31
*
259
2021 12 31
34.
2021 2020 12 31
2021 2020 2021 2020 2021 2020
68.125% – (9,624) – 371,282 –
– – (3) (3)
(9,624) – 371,279 (3)
2021 2020 12 31
2021 2020
1,167,538
1,870
(1,650)
(2,950)
793,526
371,282
260
2021 12 31
34.
2021
8 6
2021
12 31 2020
(20,568)
(9,624)
(30,192)
–
(34,024)
(24)
1,194,848
1,160,800
261
2021 12 31
35.
36.
36a.
12 31
2021 2020
4,853,831 4,088,557
1,027,108 356,742
1,710,079 1,279,634
36b.
262
2021 12 31
36.
36b.
(i)
12 31
2021 2020
1,734,299 608,851
534,495 11
(22,449) (72,394)
5% 2020 5%)
5%
5%
5% 5% 5%
263
2021 12 31
36.
36b.
(i)
12 31
2021 2020
(64,194) (20,117)
(20,044) –
(ii)
25 27
23 21
12 31
2021 2020
30,979 20,278
264
2021 12 31
36.
36b.
(ii)
12 31
2021 2020
16,053 26,312
(iii)
22
2021 12 31
5% 12,679,000
/ 5%(2020 5%)
2021 12 31 / 30,916,000 (2020 : /
3,986,000 ) 3
36
265
2021 12 31
36.
36b.
12
12
2021 12 31
97%(2020: 36%) 3% 2020 64%)
97% 2020 53%)
266
2021 12 31
36.
36b.
2020 89,000
12
2021 2020 12 31
342,000 2020 344,000
– 12
– 12
– –
267
2021 12 31
36.
36b.
– –
12
2021 2020
23 AA 12 2,033 –
23 AA 12 3,504,605 3,384,998
21 12 54,850 41,168
20
11,971 253,512
1,273,272 335,695
7,690 74,116
4,854,421 4,089,489
9
268
2021 12 31
36.
36b.
2021 2020
0.01%-0.1% 11,971 0.01% – 0.1% 253,512
1-30 – –
31-60 – –
11,971 253,512
2021 2020 12 31
2021 12 31
2020 89,000
269
2021 12 31
36.
36b.
12
2020 1 1 89 588 677
2020 1 1
(89) (326) (415)
– 670 670
2020 12 31 – 932 932
2021 1 1
– (342) (342)
2021 12 31 – 590 590
25 29
270
2021 12 31
36.
36b.
3
3 1 1-2 2-5 5
%
2021 12 31
– 1,209,483 – – – – 1,209,483 1,209,483
3.98 9,843 19,398 48,330 261,068 248,628 587,267 500,596
5.22 8,054 26,598 36,791 93,360 – 164,803 127,599
1,227,380 45,996 85,121 354,428 248,628 1,961,553 1,837,678
2020 12 31
– 485,066 – – – – 485,066 485,066
5.23 11,336 281,416 582,629 – – 875,381 794,568
5.22 8,503 23,007 17,770 21,887 – 71,167 56,211
504,905 304,423 600,399 21,887 – 1,431,614 1,335,845
271
2021 12 31
36.
36b.
(i)
2021 2020
12 31 12 31
– 17
20,000 –
1,952 1,952
27% 2020 27%)
EV/S EV/S 8.69 2020 8.69)
6,802 3,772
27% 2020 27%)
P/R&D P/R&D 2.80 2020 2.80)
2021 181,888 89,373 2021 2021
a
2020 2020 2020
26% b P/R&D
P/R&D 17.52 c
272
2021 12 31
36.
36b.
(i)
2021 2020
12 31 12 31
37,910 37,910
146,886 –
141,424 81,444 2021 2021
2020 2020
2020
81,453 65,244 2021 2021
2020 P/R&D 25% P/R&D
2020 5.39 2020
155,218 77,030 d
253,575 –
1,027,108 356,742
273
2021 12 31
36.
36b.
(i)
a. 2021 12 31
b.
0.5% 26.5%/25.5% 2020 12 31
604,000 604,000
c. P/R&D
P/R&D 5% 18.40/16.64
2020 12 31 4,469,000 4,469,000
d.
5% 2021 12 31
7,761,000 2020 3,852,000
274
2021 12 31
36.
36b.
(ii)
2020 1 1 18,000 – – 18,000
51,345 – – 51,345
– 60,000 – 60,000
(106) – – (106)
25,858 17,030 – 42,888
2020 12 31 2021 1 1 95,097 77,030 – 172,127
– – 146,688 146,688
(89,373) – 89,373 –
3,030 62,010 – 65,040
– 16,178 168,704 184,882
2021 12 31 8,754 155,218 404,765 568,737
(iii)
275
2021 12 31
37.
H
27 25 24 24
2020 1 1 41,178 821,787 – 13,565 876,530
(25,348) (70,334) – (337,730) (433,412)
3,079 43,115 – – 46,194
– – – 324,165 324,165
37,302 – – – 37,302
2020 12 31 56,211 794,568 – – 850,779
(39,739) (310,025) (29,677) – (379,441)
5,780 16,053 – – 21,833
– – 30,434 – 30,434
105,347 – – – 105,347
2021 12 31 127,599 500,596 757 – 628,952
2020 12 31 16,803,000
276
2021 12 31
38.
2 3
105,347,000 105,347,000 2020 37,302,000
37,302,000
39.
12 31
2021 2020
243,624 220,642
149,982 34,660
2,927,129 1,875,400
36,475 27,962
16,056 1,021
441,736 65,150
213,242 42,494
719,951 –
964,254 343,480
5,712,449 2,610,809
277
2021 12 31
39.
12 31
2021 2020
27,249 41,041
1,292,086 596,481
423,716 237,128
672,660 782,571
2,004,602 2,641,560
4,420,313 4,298,781
1,557,717 954,387
519,239 161,579
23,692 18,077
60,361 –
2,161,009 1,134,043
2,259,304 3,164,738
7,971,753 5,775,547
8,022 30,961
34,922 18,600
42,944 49,561
7,928,809 5,725,986
910,757 872,496
7,018,052 4,853,490
7,928,809 5,725,986
278
2021 12 31
39.
2020 1 1 4,130,575 – 37,338 – (2,174,010) 1,993,903
– – – – (1,592,375) (1,592,375)
A 4,748,585 – – – – 4,748,585
A (338,737) – – – – (338,737)
– – 6,549 – – 6,549
21,110 – (11,110) – – 10,000
– 25,565 – – – 25,565
2020 12 31 8,561,533 25,565 32,777 – (3,766,385) 4,853,490
– – – – (131,132) (131,132)
– – – 19,454 – 19,454
– – – 19,454 (131,132) (111,678)
H 2,097,832 – – – – 2,097,832
H (30,434) – – – – (30,434)
– – 2,499 – – 2,499
– 192,309 – – – 192,309
30,242 – (16,208) – – 14,034
2021 12 31 10,659,173 217,874 19,068 19,454 (3,897,517) 7,018,052
H
279
2021 12 31
40.
2022 1 10 Coherus 5
35,000,000
255,000,000
2022 3 7 35 70 A
3,980
280
2018
2018 2019 7
2018 2018 5 14
2020 7 15
2020 A 2020 11 16 2020 2020
A 2020 H
2020 A
A 1.00
A A
ASCO
50%
BLA
281
BTD
CGMP
Coherus Coherus BioSciences, Inc.
Coherus
622
COVID-19
ESG
1,400 (LY-CoV555)700
EUA
Coherus 2021 2 1
FDA
GMP
282
2018
H H 2018 12 24
H 1.00
H H
IDMC
IND
283
Eli Lilly and Company
NDA
NMPA
OS
PDUFA
PFS
284
2018
2018 12 11
2021 12 31
2020 A
A 2020 A
571
2016 6
1.00 H A
285
2018 3
sNDA
286
TopAlliance TopAlliance Biosciences Inc.
%
*